Discussion: For example, L10V, V11I/V, L33F, T69A/N/S, and P236L were present only in individuals with CRF01_AE strains.
Discussion: Other commonly observed mutations were T69A/N/S, V179E, L10I/L/V, V11I/V, L33F, and A71A/T/V; none of these mutations is known to confer drug resistance to NRTIs, NNRTIs, or PIs.
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.
Result: N[t]RTI RAMs were found in 14% of patients (43/313; 36 and seven patients), most commonly V118I (6%; 18/313; 18 and zero patients), T69D/N (3%; 8/313; eight and zero patients) and M184V/I (3%; 8/313; two and six patients).
Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV.
Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul.
PMID: 23296905
2013
Medical microbiology and immunology
Abstract: In these patients, the nucleoside reverse transcriptase inhibitor (NRTI)-associated resistance mutations M41L, T215C, V75I, T69N, the non-NRTI associated mutations V106I, E138A, K103N and the protease inhibitor associated mutations Q58E and V82I were detected.
Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.
Result: Several atypical substitutions at key positions known to be linked with drug resistance were detected also within the RT gene: for NRTI-T69S (1/61 patients), T69N (2/61 patients) and for NNRTI-E138A/ G (5/61 patients), H221Y (1/61 patients).
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
Result: The NRTI-associated mutations were D67N (2 strains), T69N (1), M184V (6), L210W (2), T215Y (2).
Table: T69N
Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
PMID: 21148504
2011
The Journal of infectious diseases
Introduction: Two other mutations (T69N and M184I) were also detected in a minority of sequences in these in vitro experiments.
Result: No cases of T69N or M
Discussion: The mutations selected in the in vitro experiments confer cross-resistance to NRTIs: V75I contributes resistance to multiple NRTIs in the presence of a concurrent Q151M mutation, T69N and other variants at position 69 are selected by didanosine and other NRTIs but their susceptibility profiles are not well-described (http://hivdb.stanford.edu/), and the variants M184I/V confer high-level resistance to lamivudine and emtricitabine.
HIV mutation literature information.
PMID: 
2014
Retrovirology
Browser Board
Co-occurred Entities
Filtrator
ViMRT